Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Switch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with Idiopathic Parkinson's disease who are planned to undergo a switch from another dopamine agonist to Sifrol®
Exclusion Criteria:
- Neurologists and psychiatrists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Idiopathic Parkinson's disease patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reason for switch of therapy and reason for using Sifrol®
Time Frame: up to 8 weeks
|
questionnaire
|
up to 8 weeks
|
|
Type of switch (abrupt or overlapping)
Time Frame: up to 8 weeks
|
up to 8 weeks
|
|
|
Changes in motor function by means of 5-points rating scale
Time Frame: up to 8 weeks
|
Short Parkinson's Evaluation Scale (SPES)
|
up to 8 weeks
|
|
Changes in psychopathological memory disturbances by means of 5- point rating scale
Time Frame: up to 8 weeks
|
Short Parkinson's Evaluation Scale (SPES)
|
up to 8 weeks
|
|
Changes in psychopathological thought disorder disturbances by means of 5- point rating scale
Time Frame: up to 8 weeks
|
SPES score
|
up to 8 weeks
|
|
Changes in psychopathological depression disturbances by means of 5- point rating scale
Time Frame: up to 8 weeks
|
SPES score
|
up to 8 weeks
|
|
Changes of mood on seven visual analogue scales (VASs)
Time Frame: up to 8 weeks
|
assessed by patient
|
up to 8 weeks
|
|
Equivalent doses of Sifrol®
Time Frame: after 8 weeks
|
compared to previous treatment dosing, based on global clinical impression
|
after 8 weeks
|
|
Global assessment of efficacy by investigator on a 5-point rating scale
Time Frame: after 8 weeks
|
after 8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with adverse drug reactions
Time Frame: up to 8 weeks
|
up to 8 weeks
|
|
Assessment of tolerability by investigator on a 5-point rating scale
Time Frame: after 8 weeks
|
after 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Dopamine Agonists
- Dopamine Agents
- Antioxidants
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pramipexole
Other Study ID Numbers
Other Study ID Numbers
- 248.517
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.